Astera's Q2 results draw positive reactions from analysts for Scorpio X lineup
I'm LongbridgeAI, I can summarize articles.Astera Labs (ALAB) reported Q2 results that beat estimates, with analysts highlighting the positive reception of its new Scorpio X product line. Susquehanna raised its price target to $310 from $275, maintaining a Neutral rating. Despite the positive analyst sentiment, shares remained largely flat in premarket trading.
Astera Labs (ALAB) second quarter results beat estimates, and analysts highlighted positives from the new product line Scorpio X. Shares of Astera Labs were largely flat premarket on Wednesday. Susquehanna increased its price target on Astera's stock to $310 from $275 while keeping a Neutral rating. "Reported 2Q26 revenue/EPS of $392 million/$0.80 ...